Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
abandon, advisor, alleviate, alternative, analyze, arrangement, assist, bankruptcy, began, bore, carefully, certificate, composition, core, decision, decline, defense, DGCL, diminished, discharged, discontinued, discontinuing, discretion, dissolution, dissolved, distributable, distribute, distributed, distribution, doubt, drew, eliminated, exact, exploration, explore, expose, external, firm, formally, fulfill, hearing, impossible, inability, incremental, indemnification, independent, insurance, intact, involuntary, January, Ladenburg, leaving, Lowey, made, maximize, merger, modify, necessity, opening, optimize, organization, organizational, Panel, partner, preserve, promptly, Proposal, provision, pursue, quickly, recoverability, reorganization, reserved, resolve, restructuring, revocation, satisfied, settlement, shell, State, stockholder, supply, team, Thalmann, trial, unanimously, unanticipated, undertook, unmatured, valid, Verdolino, voluntary, wind, winding, workforce
Removed:
AbbVie, acceptance, accessing, accounted, accrue, accuracy, acquire, acquisition, adequately, advancing, adversely, anniversary, approach, assessing, assessment, ASU, attract, award, back, bear, beginning, bid, bringing, calendar, case, closing, collaborative, commence, commencement, commercialize, competing, compound, conditionally, consecutive, contingently, continually, covering, criteria, deducting, delisting, delivery, depend, derived, develop, developed, developing, differentiate, differentiated, difficult, discount, distinct, dose, DPN, duration, eligible, ending, enroll, enrolling, enrollment, establish, establishing, evaluate, existence, expand, expanding, experienced, expertise, extension, extinguished, fail, failure, favorable, fibromyalgia, fixed, fluctuate, foreign, forward, Global, grant, guidance, healthcare, higher, hire, hiring, identified, implement, improve, inclusive, increased, infringe, initiation, issuable, issuance, issue, issuing, key, label, largely, launch, legislation, lessee, letter, leveraging, licensing, limit, limitation, liquidity, lower, manufacture, marketing, mg, milestone, minimize, misappropriate, mitigate, modulate, modulator, modulatory, monitoring, Naurex, neurodegenerative, nominal, noted, obtain, optioned, pace, pain, painful, pandemic, paradigm, personnel, phased, pipeline, plc, policy, pool, portfolio, predefined, predetermined, preparatory, prevent, protect, prove, put, qualified, RCA, reclassified, recognize, recommencement, recover, referred, reform, regulation, reimbursement, remeasured, requirement, response, retain, royalty, safety, Select, serve, shift, side, size, sooner, statistically, subsidiary, successfully, technology, temporarily, therapeutic, uncertain, unit, unvested, utility, utilize, vested, viability, violate, wholly, wrong
Financial report summary
?Management Discussion
- Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
- Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10-Q, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. See “Special Note Regarding Forward-Looking Statements.” Because of many factors, including those factors set forth in the “Risk Factors” section of our Annual Report and in section Part II, Item 1A of this Quarterly Report on Form 10-Q, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. We do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
- Until recently, we were a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel, proprietary, synthetic small molecules for the treatment of nervous system disorders. We had focused our efforts on targeting and modulating N-methyl-D-aspartate receptors, or NMDArs, which are vital to normal and effective function of the brain and nervous system.